Progressive pulmonary fibrosis
UTHRUnited TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Tyvaso (inhaled treprostinil) in Progressive pulmonary fibrosis . The expected timing is based on the latest available company guidance and may change.
TETON PPF trial. 10/31/23- First patient enrolled. 4/30/25- Enrollment ongoing. 05/11/26:- TETON-PPF interim analysis to be presented at ATS May 19, 2026. 08/17/26:- TETON-PPF fully enrolled Aug 2026. Topline Phase 3 data expected H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.